| Name | Title | Contact Details |
|---|---|---|
Michael Olszowy |
Chief Technology Officer | Profile |
Concuity is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Defyrus Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.
Marligen Biosciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.